Regeneron Pharmaceuticals, Inc.
Regeneron Reports First Quarter 2025 Financial Results and Pipeline Updates
Summary
Regeneron Pharmaceuticals, Inc. announced its first quarter 2025 financial results, showing total revenues of $3.0 billion, GAAP diluted EPS of $7.27, and non-GAAP diluted EPS of $8.22. Key highlights include a 19% increase in global net sales of Dupixent, regulatory approvals for Dupixent in chronic spontaneous urticaria (CSU) in the U.S. and chronic obstructive pulmonary disease (COPD) in Japan, and FDA acceptance for priority review of EYLEA HD for retinal vein occlusion (RVO) and monthly dosing. Additionally, Lynozyfic was approved in the EU for relapsed/refractory multiple myeloma, and regulatory applications were submitted for Libtayo in adjuvant cutaneous squamous cell carcinoma (CSCC) in the U.S. and EU. Regeneron also announced ongoing and planned investments in New York and North Carolina infrastructure and manufacturing expected to total more than $7 billion.
Profitelligence Alerts
Get alerts for REGN
Be first to know when Regeneron Pharmaceuticals, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Official SEC Documents
Advertisement